Cite
HARVARD Citation
Sigaud, R. et al. (2023). The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. Neuro-oncology. 25 (3), pp. 566-579. [Online].